Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis

Naohiro Watanabe, Hiroyuki Taniguchi, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Osamu Nishiyama, Masashi Kondo, Yoshinori Hasegawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.

Original languageEnglish
Pages (from-to)260-265
Number of pages6
JournalInternational Journal of Clinical Oncology
Volume19
Issue number2
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Idiopathic Pulmonary Fibrosis
Small Cell Lung Carcinoma
Drug Therapy
Disease-Free Survival
Survival
Observational Studies
Carcinogenesis
Retrospective Studies
Prospective Studies
Neoplasm Metastasis
Lung

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Watanabe, N., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Nishiyama, O., ... Hasegawa, Y. (2014). Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. International Journal of Clinical Oncology, 19(2), 260-265. https://doi.org/10.1007/s10147-013-0554-5
Watanabe, Naohiro ; Taniguchi, Hiroyuki ; Kondoh, Yasuhiro ; Kimura, Tomoki ; Kataoka, Kensuke ; Nishiyama, Osamu ; Kondo, Masashi ; Hasegawa, Yoshinori. / Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. In: International Journal of Clinical Oncology. 2014 ; Vol. 19, No. 2. pp. 260-265.
@article{2ef4dd88838d484188cc8b86b5fe3826,
title = "Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis",
abstract = "Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 {\%}. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.",
author = "Naohiro Watanabe and Hiroyuki Taniguchi and Yasuhiro Kondoh and Tomoki Kimura and Kensuke Kataoka and Osamu Nishiyama and Masashi Kondo and Yoshinori Hasegawa",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10147-013-0554-5",
language = "English",
volume = "19",
pages = "260--265",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "2",

}

Watanabe, N, Taniguchi, H, Kondoh, Y, Kimura, T, Kataoka, K, Nishiyama, O, Kondo, M & Hasegawa, Y 2014, 'Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis', International Journal of Clinical Oncology, vol. 19, no. 2, pp. 260-265. https://doi.org/10.1007/s10147-013-0554-5

Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. / Watanabe, Naohiro; Taniguchi, Hiroyuki; Kondoh, Yasuhiro; Kimura, Tomoki; Kataoka, Kensuke; Nishiyama, Osamu; Kondo, Masashi; Hasegawa, Yoshinori.

In: International Journal of Clinical Oncology, Vol. 19, No. 2, 01.01.2014, p. 260-265.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis

AU - Watanabe, Naohiro

AU - Taniguchi, Hiroyuki

AU - Kondoh, Yasuhiro

AU - Kimura, Tomoki

AU - Kataoka, Kensuke

AU - Nishiyama, Osamu

AU - Kondo, Masashi

AU - Hasegawa, Yoshinori

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.

AB - Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.

UR - http://www.scopus.com/inward/record.url?scp=84899988574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899988574&partnerID=8YFLogxK

U2 - 10.1007/s10147-013-0554-5

DO - 10.1007/s10147-013-0554-5

M3 - Article

VL - 19

SP - 260

EP - 265

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 2

ER -